can be used for translational use such as disease modeling of brain diseases using patient-derived cells. Similar efforts have been made for the iPS cell technology but their success is not so critical because typically only few iPS cell lines are required per patient [41–43]. So far, two approaches have been taken to optimize iN cell reprogramming which are discussed in the following.
